LMR Partners’s ClearPoint Neuro CLPT Stock Holding History

LMR Partners’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-18,124	Closed	-$215K	–	1417
2025 Q1	$215K	Buy	+18,124	New	+$282K	﹤0.01%	1046
2023 Q2	–	Sell	-13,608	Closed	-$115K	–	932
2023 Q1	$115K	Buy	+13,608	New	+$119K	﹤0.01%	923

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return

LMR Partners's CLPT Position: Q2 2025 in Review

LMR Partners sold out of ClearPoint Neuro (CLPT) in Q2 2025, closing a stake of 18,124 shares — an estimated $215K sold.

LMR Partners first reported a position in CLPT in Q1 2023 and held it in 2 quarters. The position peaked at $215K in Q1 2025. 96 funds tracked by Wall St. Rank hold CLPT as of Q2 2025.

LMR Partners reported no remaining ClearPoint Neuro position as of Q2 2025 after selling out during the quarter.
LMR Partners sold 18,124 ClearPoint Neuro shares in Q2 2025, an estimated $215K.
LMR Partners first reported a position in ClearPoint Neuro in Q1 2023 and held it in 2 quarters.
LMR Partners's ClearPoint Neuro position peaked at $215K in Q1 2025.
96 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2025.

Based on LMR Partners's 13F filing for Q2 2025, filed 14 Aug 2025.